1287766-55-5
1287766-55-5
Chemical Structure
Tigulixostat
Synonym(s): LC350189
- CAS. Nr.: 1287766-55-5
- Formula:C16H14N4O2
- Molecular Weight:294.31
IUPAC Name: 1-(3-cyano-1-isopropyl-1H-indol-5-yl)-1H-pyrazole-4-carboxylic acid
InChIKey: JLQQRYOWGCIMMZ-UHFFFAOYSA-N
SMILES: N#CC1=CN(C(C)C)C2=C1C=C(N3N=CC(C(O)=O)=C3)C=C2
Biological Activity: Tigulixostat (LC350189) is an orally active non-purine selective xanthine oxidase inhibitor. Tigulixostat has IC50 values of 0.003 µM and 0.073 µM in bovine milk and rat plasma, respectively. Tigulixostat can effectively reduce serum uric acid levels and can be used in the research of gout and hyperuricemia[1][2][3][4].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tigulixostat | 99.18% | Tigulixostat (LC350189) is an orally active non-purine selective xanthine oxidase inhibitor. Tigulixostat has IC50 values of 0.003 µM and 0.073 µM in bovine milk and rat plasma, respectively. Tigulixostat can effectively reduce serum uric acid levels and can be used in the research of gout and hyperuricemia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Seonghae Yoon, et al. Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. Drug Des Devel Ther. 2015 Aug 31;9:5033-49. [Content Brief]
- [2]. Terkeltaub R, et al. Serum Urate-Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Trial. Arthritis Rheumatol. 2023 Jul;75(7):1275-1284. [Content Brief]
- [3]. Xue L, et al. Tigulixostat Alleviates Hyperuricemic Nephropathy by Promoting M2 Macrophage Polarization. J Inflamm Res. 2025 Jan 3;18:17-30. [Content Brief]
- [4]. Kumar A, et al. AB0101 PRECLINICAL IN VITRO AND IN VIVO EFFICACY STUDIES OF TIGULIXOSTAT, A SELECTIVE NON-PURINE XANTHINE OXIDASE INHIBITOR. Annals of the Rheumatic Diseases, 2024, 83: 1284.
